window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 27, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

generalised anxiety disorder

  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Incannex links PSX-001 psilocybin programme to White House push on psychedelic mental health treatments

    Incannex Healthcare has said its PSX-001 oral synthetic psilocybin programme [...]

    May 14, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Lonza expands ADC drug product capacity in Switzerland
    Categories: Advanced Therapies, Biotech & Pharma Business, Drug Delivery & Formulation, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics
  • Brain network dynamics may better explain psychiatric symptoms than diagnoses
    Categories: Central Nervous System, Research & Development
  • India’s CDMO market needs science, not just scale, says Lupin Manufacturing Solutions CEO
    Categories: Biotech & Pharma Business, Digital & Data, Drug Discovery & Development, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top